China FDA issues 'user-friendly' guidance on medical device registration studies; waivers may prove a challenge
This article was originally published in SRA
Executive Summary
The China Food and Drug Administration has for the first time issued guidance that explains how medical device makers should conduct clinical evaluations of the products they seek to register in China and in which cases they may obtain a clinical study waiver1.
You may also be interested in...
China's Medtech Regulatory Reforms Yet To Enter Steady Path
Medical device companies operating in China are still looking for clearer guidance that will help them make the most of the wide-ranging regulatory reforms introduced in the country since 2014.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.